BioHarvest Sciences Inc. (BHST)
| Market Cap | 97.47M |
| Revenue (ttm) | 34.51M |
| Net Income (ttm) | -11.14M |
| Shares Out | 22.67M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,801 |
| Open | 4.300 |
| Previous Close | 4.380 |
| Day's Range | 4.270 - 4.360 |
| 52-Week Range | 4.100 - 12.800 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+132.56%) |
| Earnings Date | May 14, 2026 |
About BHST
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through Nutraceuticals and Pharmaceuticals segments. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional foods, as well as manufacturing, marketing, and... [Read more]
Financial Performance
In 2025, BioHarvest Sciences's revenue was $34.51 million, an increase of 37.00% compared to the previous year's $25.19 million. Losses were -$11.14 million, -13.77% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BHST stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
BioHarvest Sciences Earnings Call Transcript: Q4 2025
Q4 and full-year revenues grew 25% and 37% year-over-year, with gross margins improving to 58–59%. The D2C business, led by VINIA, achieved US category leadership, while the CDMO division advanced four major programs and expects to double or triple revenue in 2026.
BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results
FY2025 Revenues were $34.5 million, up 37% vs previous year. The VINIA brand has achieved the No.1 resveratrol polyphenol position in the United States Market*.
BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform
CDMO division has successfully completed Stage 1 under a development contract Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHS...
BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States
VINIA's leadership position in the market validates its superior arterial dilation and blood flow performance as well as BioHarvest's Botanical Synthesis platform technology Vancouver, British Columbi...
BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its propr...
BioHarvest Sciences Announces Grant of Long-Term Incentive Awards to Employees, Officers and Directors
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanica...
BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology,...
BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical...
BioHarvest Sciences Issues Year End Shareholder Letter
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc. , (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its pa...
BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc . (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pi...
BioHarvest Sciences Announces Launch of VINIA Blood Flow Hydration Product
First Hydration Formula Powered by VINIA's Blood Flow Technology Enters the $13 Billion U.S. Electrolyte Market Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 3, 2025) - B...
BioHarvest Sciences Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 39% year-over-year to $9.1M, driven by core products and surging CDMO services. Gross margin improved to 61%, and recent $30.8M in financing fully funds expansion, including new product launches and manufacturing scale-up.
BioHarvest Sciences Reports Third Quarter 2025 Financial Results
Strong VINIA Momentum and New CDMO Win Delivers 39% Year-Over-Year Growth Company Fortifies Balance Sheet with Recent $19.9 Million Instiutional Equity Raise Following $14.7 Million Strengthening of B...
BioHarvest Sciences to Attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its pa...
BioHarvest Sciences Announces Closing of $19.9 Million Upsized Public Offering of Common Stock and Exercise of Underwriter's Option to Purchase Additional Shares
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its pa...
BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its pat...
BioHarvest Announces Proposed Public Offering of Common Stock
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its pat...
BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m. Eastern Time
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its pat...
BioHarvest Sciences Announces Strategic CDMO Partnership to Revolutionize Saffron Compound Production with Botanical Synthesis
Partnership with "Saffron Tech" to Advance Production of One of the World's Most Valuable Botanicals Management Concurrently Shares Third Quarter 2025 Preliminary Results and Provides Guidance for the...
BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and Additional $3.8 Million in Debt Reduction
Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis te...
BioHarvest Sciences Transcript: Status Update
A major breakthrough enables scalable production of plant exosomes with unique bioactive compounds, opening new revenue streams in cosmetics, pharma, and nutraceuticals. Commercialization is underway, with direct-to-consumer, B2B, and CDMO opportunities, and a new hydration product launch and HealthPros affiliate system driving growth.
BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale
Exosomes Produced in the Liquid Media of the BioHarvest Unique Large-Scale Bioreactors Add Potential New Revenue Stream from Products and CDMO Opportunities Rehovot, Israel--(Newsfile Corp. - Septembe...
BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET
Rehovot, Israel--(Newsfile Corp. - September 2, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis techn...
BioHarvest Sciences Transcript: Canaccord Genuity’s 45th Annual Growth Conference
A leading plant cell biology innovator detailed its dual business model, highlighting strong growth in direct-to-consumer health products and rapid expansion of its high-margin CDMO partnerships. The company projects further margin gains and positive EBITDA by year-end.
BioHarvest Sciences Earnings Call Transcript: Q2 2025
Q2 2025 revenue rose 41% to $8.5M with gross margin expanding to 60%. New product launches, Health Pros channel, and CDMO pipeline growth position the company for adjusted EBITDA breakeven in Q4 2025 and further margin gains, despite tariff headwinds.